PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Pedro Carvajal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, School of Medicine, Pontificia Universidad Católica de Chile, Chile. Hauptthemen laut MEDLINE: Conjunctival Neoplasms, Melanoma, Antigens, Neoplasm, MART-1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Pontificia Universidad Católica de Chile.
Abstract (Originalsprache)
INTRODUCTION: PRAME (PReferentially expressed Antigen in Melanoma) is an antigen that is predominantly expressed in human melanomas. In cutaneous melanocytic lesions, PRAME expression is associated with malignancy. The objective of this study was to evaluate the co-expression of PRAME and Melan A to evaluate their diagnostic value in different conjunctival melanocytic lesions (CML). METHODS: 37 CML (23 nevi, 9 primary acquired melanosis (PAM), and 5 conjunctival melanomas) were evaluated by immunohistochemistry for PRAME and Melan-A. The percentage of melanocytic cells co-expressing PRAME and Melan-A was qualitatively evaluated as follows: negative, 0%; 1 + , 1-25%; 2 + , 26-50%; 3 + , 51-75% and 4 + , ≥ 76%. RESULTS: Of the invasive melanoma cases, 80% showed a 4 + pattern of marking, whereas 20% showed a 3 + pattern. 11% of the PAMs showed a 4 + pattern and 88.9% showed a 1 + pattern. All the nevi showed a 1 + pattern. The sensitivity and specificity of PRAME 4 + for differentiating high-grade CML from the benign and low-grade grouped CML are 93% and 100%, respectively. CONCLUSION: PRAME/MELAN-A double immunostain is particularly useful to differentiate benign from malignant conjunctival melanocytic lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology Department, School of Medicine, Pontificia Universidad Católica de Chile, Chile.
- Pathology Department, School of Medicine, Pontificia Universidad Católica de Chile, Chile. Electronic address: Zoroquiain@gmail.com.
Förderung
- Pontificia Universidad Católica de Chile
Zitieren
APA
Carvajal, P., & Zoroquiain, P. (2023). PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154776
Vancouver
Carvajal P, Zoroquiain P. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154776
BibTeX
@article{Carvajal2023,
author = {Carvajal, Pedro and Zoroquiain, Pablo},
title = {PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154776}
}
EUVIMED